Notes on pharmaceutical sourcing.
Technical writing for procurement and regulatory teams: sourcing routes, filings, and what actually matters when you build on a supplier.
- ReadJune 18, 2026 · 6 min read
Comparing GLP-1 API sourcing routes
Solid-phase synthesis, recombinant expression, and hybrid routes each shape the cost, purity profile and regulatory story of a GLP-1 API. A practical comparison for sourcing teams.
- ReadJune 2, 2026 · 5 min read
What a US DMF means for your filing
A US Drug Master File lets an API maker share confidential manufacturing detail with the FDA without exposing it to you. Here is what a DMF is, what it isn't, and how to use one.
- ReadMay 20, 2026 · 7 min read
Biosimilar technology transfer, step by step
Moving a biosimilar onto your site is less about the recipe and more about reproducing a process. A practical map of a biologics tech transfer, from gap assessment to PPQ.
- ReadMay 6, 2026 · 5 min read
CEP vs. US DMF: which filing, which market
CEP, US DMF and ASMF solve the same problem differently. Which one you need depends on where you're filing. A quick map for regulatory and sourcing teams.